Agenus Inc. (MUN:AJ8) Financings
Financings
| Raise | Date |
|---|---|
| Private placement of common stock or pre-funded warrants with Series A and Series B purchase warrants Announced: US$85M–US$340M · an accompanying Series A purchase warrant and Series B purchase warrant that, if fully… Buyers: Commodore Capital; RA Capital Management; TCGX; Invus; Ligand Pharmaceuticals Use of proceeds: Advance BOT+BAL in neoadjuvant MSS colon cancer, including the registrational Phase 3 ROBBIN trial | Jul 13, 2026 |
| Strategic investment of common stock Closed: US$16M raised · US$7.5 a share · Porrima Ltd +1 Dealers: Porrima Ltd, Biotech Value Advisors (BVA) Buyers: Zydus ($16 million of Agenus common stock (~2.1 million shares at $7.50 per share)) | Jan 15, 2026 |
| Strategic investment of common stock Announced: about US$16M · US$7.5 a share Buyers: Zydus (approximately 2.1 million shares of common stock at $7.50 per share, approximately $16 million) Use of proceeds: Working capital and general corporate purposes, and to accelerate clinical development, registration and potential commercialization of BOT/BAL | Jun 3, 2025 |